Cambridge, UK – June 13th 2023 – Torx ® Software Limited, announces the release of Torx 2.0, extending the platform’s scientific reach and capabilities to deliver unrivalled seamless integration across the drug discovery Design-Make-Test-Analyze (DMTA) cycle.
Torx is a visual, chemistry aware, cloud-native platform. By enabling chemistry teams to design molecules, track compound synthesis from start to finish and gain insightful analysis, Torx inspires discovery chemistry teams to work together and deliver faster. Benefits and features Torx 2.0 delivers include:
● New holistic view of all Test requests across Biology, Physicochemical and ADME departments that enables both visualization of existing and scheduling of new tests for individual, sets or all project compounds.
● Integration with CAS SciFinder, offering easy interrogation of synthetic feasibility, reagent availability and any patentability issues.
● Live merging of data from multiple corporate repositories with existing molecule design data, giving medicinal chemists the complete picture for decision making and progressing to the next DMTA cycle.
About Torx Software
Torx software is the synergistic collaboration
between Cresset and Elixir Software, producing the only complete DMTA
(design-make-test-analyze) solution on the market. Its visual web-based
platform enables medicinal/synthetic chemists and research teams to coordinate
efforts and optimize the entire molecule design, compound synthesis, testing
and data analysis cycle. For more information visit www.torx-software.com